{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:02:47Z","timestamp":1792713767373,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1038\/s41388-025-03322-2","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T16:06:47Z","timestamp":1740845207000},"page":"1463-1474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-5011","authenticated-orcid":false,"given":"Kai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangnan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-5043","authenticated-orcid":false,"given":"Enwu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-4097","authenticated-orcid":false,"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1647-0253","authenticated-orcid":false,"given":"PengYuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"3322_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3322\/caac.21766","volume":"73","author":"V Wadhwa","year":"2023","unstructured":"Wadhwa V, Patel N, Grover D, Ali FS, Thosani N. Interventional gastroenterology in oncology. CA Cancer J Clin. 2023;73:286\u2013319.","journal-title":"CA Cancer J Clin"},{"key":"3322_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41575-022-00726-3","volume":"20","author":"J Huang","year":"2023","unstructured":"Huang J, Lucero-Prisno DE 3rd, Zhang L, Xu W, Wong SH, Ng SC, et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. 2023;20:271\u201387.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.trecan.2022.11.003","volume":"9","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Subbiah V. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends cancer. 2023;9:237\u201349.","journal-title":"Trends cancer"},{"key":"3322_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22:3.","journal-title":"Mol Cancer"},{"key":"3322_CR6","doi-asserted-by":"publisher","first-page":"e003737.","DOI":"10.1136\/jitc-2021-003737","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen H, Yang Y, Deng Y, Wei F, Zhao Q, Liu Y. et al. Delivery of CD47 blocker SIRPalpha-Fc by CAR-T cells enhances antitumor efficacy. J Immunother Cancer. 2022;10:e003737.","journal-title":"J Immunother Cancer"},{"key":"3322_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37863-5","volume":"14","author":"E Ruffo","year":"2023","unstructured":"Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A., et al. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023;14:2463.","journal-title":"Nat Commun"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"564.","DOI":"10.3390\/ijms25010564","volume":"25","author":"S Wang","year":"2024","unstructured":"Wang S, Wei W, Yuan Y, Guo J, Liang D, Zhao X. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts. Int J Mol Sci. 2024;25:564.","journal-title":"Int J Mol Sci"},{"key":"3322_CR9","doi-asserted-by":"publisher","first-page":"96.","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Chen T, Li X, Zhang H, Li Y, Zhang S. et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Exper Hematol Oncol. 2024;13:96.","journal-title":"Exper Hematol Oncol"},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","volume":"10","author":"AR S\u00e1nchez-Paulete","year":"2022","unstructured":"S\u00e1nchez-Paulete AR, Mateus-Tique J, Mollaoglu G, Nielsen SR, Marks A, Lakshmi A, et al. Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity. Cancer Immunol Res. 2022;10:1354\u201369.","journal-title":"Cancer Immunol Res"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"e004400.","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N. et al. PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163. M2 macrophages. J Immunother Cancer. 2022;10:e004400.","journal-title":"J Immunother Cancer"},{"key":"3322_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:58.","journal-title":"Mol Cancer"},{"key":"3322_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:53.","journal-title":"J Immunother Cancer"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.actbio.2024.07.042","volume":"186","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yue L, Cao L, Liu K, Yang S, Liang S, et al. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery. Acta Biomater. 2024;186:369\u201382.","journal-title":"Acta Biomater"},{"key":"3322_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11911-5","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10:3974.","journal-title":"Nat Commun"},{"key":"3322_CR16","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/cas.13324","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108:1934\u20138.","journal-title":"Cancer Sci"},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"922.","DOI":"10.3390\/ijms21030922","volume":"21","author":"R Molfetta","year":"2020","unstructured":"Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C. et al. CD155: A multi-functional molecule in tumor progression. Int J Mol Sci. 2020;21:922.","journal-title":"Int J Mol Sci"},{"key":"3322_CR18","doi-asserted-by":"publisher","first-page":"216381.","DOI":"10.1016\/j.canlet.2023.216381","volume":"573","author":"R Zhou","year":"2023","unstructured":"Zhou R, Chen S, Wu Q, Liu L, Wang Y, Mo Y. et al. CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett. 2023;573:216381.","journal-title":"Cancer Lett."},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ. Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol. 2020;65:189\u201396.","journal-title":"Semin Cancer Biol"},{"key":"3322_CR20","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","volume":"7","author":"L Wu","year":"2019","unstructured":"Wu L, Mao L, Liu JF, Chen L, Yu GT, Yang LL, et al. Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res. 2019;7:1700\u201313.","journal-title":"Cancer Immunol Res"},{"key":"3322_CR21","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-19-3925","volume":"26","author":"A Lepletier","year":"2020","unstructured":"Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li X-Y, McDonald E. et al. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clin Cancer Res.2020;26:3671\u20133681.","journal-title":"Clin Cancer Res."},{"key":"3322_CR22","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709\u201320.","journal-title":"Blood"},{"key":"3322_CR23","doi-asserted-by":"publisher","first-page":"e54406.","DOI":"10.1371\/journal.pone.0054406","volume":"8","author":"LL Lenz","year":"2013","unstructured":"Lenz LL, Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JSB. et al. Toll-Like Receptor Ligands Induce Expression of the Costimulatory Molecule CD155 on Antigen-Presenting Cells. PLoS ONE. 2013;8:e54406.","journal-title":"PLoS ONE"},{"key":"3322_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.immuni.2022.12.010","volume":"56","author":"D Briukhovetska","year":"2023","unstructured":"Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schubel M, et al. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity. 2023;56:143\u2013161.e111.","journal-title":"Immunity"},{"key":"3322_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10:4016.","journal-title":"Nat Commun"},{"key":"3322_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s42003-020-1077-z","volume":"3","author":"AL Peille","year":"2020","unstructured":"Peille AL, Vuaroqueaux V, Wong SS, Ting J, Klingner K, Zeitouni B, et al. Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma. Commun Biol. 2020;3:367.","journal-title":"Commun Biol"},{"key":"3322_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O\u2019Connor RS, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12:877.","journal-title":"Nat Commun"},{"key":"3322_CR28","doi-asserted-by":"publisher","first-page":"e004219.","DOI":"10.1136\/jitc-2021-004219","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J. et al. Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. 2022;10:e004219.","journal-title":"J Immunother Cancer"},{"key":"3322_CR29","doi-asserted-by":"publisher","first-page":"e003237.","DOI":"10.1136\/jitc-2021-003237","volume":"9","author":"SA Nalawade","year":"2021","unstructured":"Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L. et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021;9:e003237.","journal-title":"J Immunother Cancer"},{"key":"3322_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00018-022-04524-7","volume":"79","author":"AV Melendez","year":"2022","unstructured":"Melendez AV, Velasco Cardenas RM, Lagies S, Strietz J, Siukstaite L, Thomas OS, et al. Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells. Cell Mol Life Sci. 2022;79:513.","journal-title":"Cell Mol Life Sci"},{"key":"3322_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121459","volume":"318","author":"M Entezam","year":"2023","unstructured":"Entezam M, Sanaei MJ, Mirzaei Y, Mer AH, Abdollahpour-Alitappeh M, Azadegan-Dehkordi F, et al. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sci. 2023;318:121459.","journal-title":"Life Sci"},{"key":"3322_CR32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24:1277\u201386.","journal-title":"Clin Cancer Res"},{"key":"3322_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther. 2017;25:1248\u201358.","journal-title":"Mol Ther"},{"key":"3322_CR34","doi-asserted-by":"publisher","first-page":"e000957.","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8:e000957.","journal-title":"J Immunother Cancer"},{"key":"3322_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S2352-4642(23)00031-7","volume":"7","author":"EM Thompson","year":"2023","unstructured":"Thompson EM, Landi D, Brown MC, Friedman HS, McLendon R, Herndon JE. et al. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. The Lancet Child & adolescent health. 2023;7:471\u2013478.","journal-title":"The Lancet Child & adolescent health"},{"key":"3322_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215830","volume":"545","author":"M Zhan","year":"2022","unstructured":"Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, et al. CD155 in tumor progression and targeted therapy. Cancer Lett. 2022;545:215830.","journal-title":"Cancer Lett"},{"key":"3322_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Kucan Brlic","year":"2019","unstructured":"Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16:40\u201352.","journal-title":"Cell Mol Immunol"},{"key":"3322_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03480-x","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, Wang A, Liu X, Han S, Sun Y, Zhang J, et al. Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer. J Transl Med. 2022;20:280.","journal-title":"J Transl Med"},{"key":"3322_CR39","doi-asserted-by":"crossref","unstructured":"Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA., et al. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer 2021; 9.","DOI":"10.1136\/jitc-2020-002203"},{"key":"3322_CR40","doi-asserted-by":"crossref","unstructured":"Nix MA, Wiita AP. Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy 2024.","DOI":"10.1016\/j.jcyt.2024.02.024"},{"key":"3322_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-014-1648-2","volume":"64","author":"M-R Wu","year":"2014","unstructured":"Wu M-R, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunology, Immunotherapy. 2014;64:409\u201318.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"3322_CR42","doi-asserted-by":"publisher","first-page":"e2207067.","DOI":"10.1002\/advs.202207067","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Wang K, Yang C, Zhu K, Jiang C, Wang M. et al. Tumor-Associated Macrophage-Derived Exosomal LINC01232 Induces the Immune Escape in Glioma by Decreasing Surface MHC-I Expression. Adv Sci(Weinh). 2023;10:e2207067.","journal-title":"Adv Sci(Weinh)"},{"key":"3322_CR43","doi-asserted-by":"publisher","first-page":"e2206889.","DOI":"10.1002\/advs.202206889","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang D, Cheng C, Chen X, Wang J, Liu K, Jing N. et al. IL-1\u00e1 Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer. Adv Sci (Weinh). 2023;10:e2206889.","journal-title":"Adv Sci (Weinh)"},{"key":"3322_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.tcb.2023.03.008","volume":"33","author":"J Liu","year":"2023","unstructured":"Liu J, Cao X. Glucose metabolism of TAMs in tumor chemoresistance and metastasis. Trends in Cell Biol. 2023;33:967\u2013978.","journal-title":"Trends in Cell Biol"},{"key":"3322_CR45","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, Lu S, Zhang H, Zhang L, Dai Z, Kaufman DS. et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends in Biotechnol. 2023;41:907\u2013922.","journal-title":"Trends in Biotechnol"},{"key":"3322_CR46","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","volume":"27","author":"X Lei","year":"2021","unstructured":"Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021;27:3757\u201371.","journal-title":"Clin Cancer Res"},{"key":"3322_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25417-6","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Lu D, Yin Y, Song J, Liu Y, Hao W, et al. PTENalpha functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer. Nat Commun. 2021;12:5147.","journal-title":"Nat Commun"},{"key":"3322_CR48","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1093\/brain\/awaa273","volume":"143","author":"AC Fuentes-Fayos","year":"2020","unstructured":"Fuentes-Fayos AC, Vazquez-Borrego MC, Jimenez-Vacas JM, Bejarano L, Pedraza-Arevalo S, L-L\u00f3pez F, et al. Splicing machinery dysregulation drives glioblastoma development\/aggressiveness: oncogenic role of SRSF3. Brain. 2020;143:3273\u201393.","journal-title":"Brain"},{"key":"3322_CR49","doi-asserted-by":"publisher","first-page":"585.","DOI":"10.3390\/cells8060585","volume":"8","author":"T Kuwata","year":"2019","unstructured":"Kuwata T, Yanagihara K, Iino Y, Komatsu T, Ochiai A, Sekine S. et al. Establishment of Novel GastricCancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor,Patient-Derived, and Cell-Line Derived Xenografts. Cells. 2019;8:585.","journal-title":"Cells"},{"key":"3322_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20207-y","volume":"11","author":"KC Chang","year":"2020","unstructured":"Chang KC, Diermeier SD, Yu AT, Brine LD, Russo S, Bhatia S, et al. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nat Commun. 2020;11:6438.","journal-title":"Nat Commun"},{"key":"3322_CR51","doi-asserted-by":"publisher","first-page":"759.","DOI":"10.3390\/cancers16040759","volume":"16","author":"C Wang","year":"2024","unstructured":"Wang C, Xie G-M, Zhang L-P, Yan S, Xu J-L, Han Y-L. et al. High Engraftment and Metastatic Rates in Orthotopic Xenograft Models of Gastric Cancer via Direct Implantation of Tumor Cell Suspensions. Cancers. 2024;16:759.","journal-title":"Cancers"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03322-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T09:02:58Z","timestamp":1747126978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03322-2","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committees of the third affiliated hospital of Zhengzhou University (2023-045), all methods were performed in accordance with the relevant guidelines and regulations, and informed consent was obtained from all participants included in the study, in agreement with institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}